 |
|
|
| |
Outcomes of Cabotegravir (CAB) Treatment in HIV-1 ART-Naive Patients With Chronic or Acute Hepatitis C Virus (HCV) Co-infection: Data From the Phase IIbProgramme
|
| |
| |
"10 of 490 (2%) subjects in the LATTE and LATTE-2 studies developed acute HCV infection while on CAB, characterised by ATEs"
"Acute HCV infection was the most frequent explanation for subjects with ATEs meeting LSC during the course of the phase IIbstudies, particularly in LATTE-2. Our data appear to be consistent with the emerging HCV epidemic reported among HIV-positive MSM that is concentrated in certain geographical areas, such as Europe3"
Reported by Jules Levin
HIV Glasgow Oct 23-26 2016
S Thiagarajah,1D Dorey,2J Huang,2G Roberts,1 B Stancil,3 D Margolis4
1-2GlaxoSmithKline, 1Global Clinical Safety and Pharmacovigilance, StockleyPark, UK; 2Clinical Statistics, Mississauga, Canada; 3PAREXEL, International, Durham, NC, USA; 4ViiV Healthcare, Global Medical Strategy, Durham, NC, USA
|
| |
|
|
|
|
|
